|
|
| | Budigalimab Basic information |
| Product Name: | Budigalimab | | Synonyms: | Budigalimab;Research Grade Budigalimab (DHH02210);Research Grade Budigalimab;Budigalimab (anti-PD-1) | | CAS: | 2098225-93-3 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Budigalimab Structure]() |
| | Budigalimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Budigalimab Usage And Synthesis |
| Uses | Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors[1]. | | References | [1] Powderly J, et al. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). Clin Transl Sci. 2021 Jan;14(1):277-287. DOI:10.1111/cts.12855 |
| | Budigalimab Preparation Products And Raw materials |
|